Recent attention on Liquidia (LQDA) has centered on accelerating use of its dry powder treprostinil therapy, YUTREPIA, in pulmonary hypertension, supported by endorsement from billionaire investor Tom Steyer and management’s 2027 franchise ambitions.

That enthusiasm has been reflected in the share price, with the latest close at $40.13 and a 1 year total shareholder return of 158.32%, even though the 90 day share price return shows a 9.68% decline.

If the YUTREPIA story has you looking wider across healthcare and AI, it could be a good moment to scan 35 healthcare AI stocks

With Liquidia now valued at around US$3.4b and the stock already up very sharply over the past 3 years, the key question is simple: are you looking at an underappreciated growth story or a market that has already priced in the future?

Most Popular Narrative: 8.8% Undervalued

The most followed valuation view for Liquidia points to a fair value of $44.00 versus the recent $40.13 share price, framing the stock as modestly undervalued on that basis.

Rapid early adoption of YUTREPIA, with more than 900 prescriptions and over 550 patient starts in about 11 weeks, points to growing physician and patient acceptance of inhaled treprostinil delivered via PRINT technology. This can support prescription volume and product revenue as awareness broadens across the 6,500 targeted prescribers.

Curious what kind of revenue ramp, margin shift and future earnings power are baked into that $44.00 fair value? The narrative focuses on strong growth assumptions, a shift toward profitability and a future earnings multiple that depends on effective execution.

Result: Fair Value of $44.00 (UNDERVALUED)

However, there are clear pressure points, including heavy reliance on voucher and bridge programs, as well as the risk that new manufacturing capacity runs ahead of sustainable YUTREPIA demand.

Another View: Rich Multiples Against Bullish Narratives

Those fair value estimates sit alongside a very different signal from simple P/S math. Liquidia trades at a P/S of 22.5x, versus an estimated fair ratio of 11.1x, around 7.5x for peers and 5.3x for the wider US pharmaceuticals group. That gap raises a basic question for you: are expectations running too far ahead of the business, or is the market still catching up?

Next Steps

With such mixed signals around valuation and expectations, it makes sense to move quickly and test the story against the underlying data yourself. To weigh up what the market might be getting right or wrong, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If YUTREPIA has caught your attention, do not stop at a single stock. Cast the net wider now so you do not miss other compelling opportunities.

• Spot potential turnaround stories before the crowd by scanning 22 elite penny stocks with strong financials that already pair low share prices with stronger underlying financials.
• Zero in on quality at a reasonable price by reviewing the 52 high quality undervalued stocks that combine solid cash flows with healthier balance sheets.
• Prioritize resilience and sleep better at night by focusing on 72 resilient stocks with low risk scores that carry lower risk scores yet still offer meaningful exposure to equities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.